Drug Profile
IDN 6439
Alternative Names: IDN-6439Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Indena; University of Camerino; University of Turin
- Developer Indena
- Class Cancer vaccines
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Head and neck cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Head-and-neck-cancer in Italy